moderate - Cardiovascular segment (65-70% of revenue) is tied to elective cardiac surgery volumes, which decline 10-15% during recessions as hospitals defer non-emergency procedures and patients delay treatment. Neuromodulation segment is more defensive as epilepsy treatment is non-discretionary, though depression indication adoption may slow with reduced healthcare spending. Hospital capital equipment budgets are pro-cyclical, affecting heart-lung machine sales. Overall revenue correlation to GDP growth is ~0.6x given mix of elective and essential procedures.

Rising rates have modest negative impact through two channels: (1) Hospital capital budgets tighten as borrowing costs increase, potentially delaying heart-lung machine purchases (15-20% of Cardiovascular revenue); (2) Higher discount rates compress valuation multiples for med-tech growth stocks. However, limited direct debt refinancing risk given moderate 0.42 Debt/Equity ratio. Company benefits from floating-rate assets (cash) exceeding floating-rate liabilities. Net impact: mildly negative on valuation, minimal on operations.

growth - Investors focus on Neuromodulation segment's expansion potential in underpenetrated TRD market (estimated $3B+ opportunity) and international Cardiovascular growth in emerging markets. Recent 42.4% one-year return and 260% net income growth attract momentum investors, though growth is from low base following restructuring. Valuation at 2.7x Price/Sales is premium to diversified med-tech (2.0x average) but below pure-play neuromodulation peers (3.5-4.0x), appealing to GARP investors seeking recovery stories with operating leverage.